eCite Digital Repository

Targeting LIN28: A new hope in prostate cancer theranostics

Citation

Shrivastava, G and Aljabali, AAA and Shahcheraghi, SH and Lotfi, M and Shastri, M and Shukla, SD and Chellappan, DK and Jha, NK and Anand, K and Dureja, H and Pabari, RM and Mishra, V and Almutary, AG and Alnuqaydan, AM and Charbe, N and Prasher, P and Negi, P and Goyal, R and Dua, K and Gupta, G and Serrano-Aroca, A and Bahar, B and Barh, D and Panda, PK and Takayama, K and Lundstorm, K and McCarron, P and Bakshi, H and Tambuwala, MM, Targeting LIN28: A new hope in prostate cancer theranostics, Future Oncology, 17, (29) pp. 3873-3880. ISSN 1479-6694 (2021) [Refereed Article]


Preview
PDF
Pending copyright assessment - Request a copy
3Mb
  

DOI: doi:10.2217/fon-2021-0247

Abstract

The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.

Item Details

Item Type:Refereed Article
Keywords:LIN28A, LIN28B, biomarker, prostate cancer, theranostic
Research Division:Biomedical and Clinical Sciences
Research Group:Oncology and carcinogenesis
Research Field:Cancer therapy (excl. chemotherapy and radiation therapy)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Treatment of human diseases and conditions
UTAS Author:Shastri, M (Mr Madhur Shastri)
ID Code:151675
Year Published:2021
Web of Science® Times Cited:1
Deposited By:Pharmacy
Deposited On:2022-08-03
Last Modified:2022-08-03
Downloads:0

Repository Staff Only: item control page